文章核心观点 - 艾利利利公司(Eli Lilly)的新药物tirzepatide在治疗肥胖、2型糖尿病等疾病方面取得了巨大成功,销售额超过10亿美元 [4] - tirzepatide还可能在治疗阻塞性睡眠呼吸暂停和心力衰竭等疾病方面获得监管机构的批准 [5] - 艾利利利公司正在研究将tirzepatide与其他药物如Taltz联合用于治疗银屑病等免疫性疾病,这可能会对阿博特公司(AbbVie)的业务产生影响 [7][8][9] - 虽然目前tirzepatide在免疫性疾病领域的应用还需要一些时间,但其跨入免疫领域的潜力巨大,可能会对阿博特公司的主导地位构成挑战 [10][11][12] 公司相关 - 艾利利利公司的研发工作仍在持续,正在探索将tirzepatide与其他药物联合用于治疗更多疾病 [6][9] - 艾利利利公司正在加大对tirzepatide的研发投入,希望进一步拓展其适应症 [6] - 艾利利利公司的tirzepatide可能会对阿博特公司的主导地位构成挑战,但这种影响还需要一些时间 [13][14] - 艾利利利公司的一些扩展tirzepatide适应症的尝试可能会失败,需要关注哪些尝试可能带来最大的财务影响 [15] 行业相关 - tirzepatide跨入免疫性疾病领域的潜力巨大,可能会对阿博特公司的主导地位产生影响 [10][11][12] - 诺和诺德公司的药物semaglutide也显示出可能有助于治疗银屑病的潜力,与tirzepatide的作用机制相似 [8] - 阿博特公司的主导产品Humira专利保护期已经结束,市场份额正在被仿制药快速侵蚀 [10] - 阿博特公司开发的替代Humira的新药Skyrizi和Rinvoq在免疫性疾病领域的覆盖范围与Humira大致相同 [11]

amphotora/E+ via Getty Images Introduction On May 29, I wrote an article titled "Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered." Since then, shares of the Abbott Laboratories (ABT) spin-off have returned roughly 30%, beating the S&P 500 by 23 points. Since becoming independent in April 2012, AbbVie Inc. (NYSE:ABBV) has returned 810%, beating both the S&P 500 and the healthcare ETF (XLV). Data by YCharts Although I'm obviously happy, my thesis has turned out to be correct, it's impor ...

More than 400 undergraduate and graduate students in the U.S. have benefited from the AbbVie Immunology Scholarship since its inception in 2016NORTH CHICAGO, Ill., Aug. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the 2024-2025 recipients of the AbbVie Immunology Scholarship, aimed to support students living with chronic, inflammatory diseases as they pursue higher education.Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/9253951-abbvie-immuno ...

SkinMedica®, by the makers of BOTOX® Cosmetic (onabotulinumtoxinA) launches the first and only product to use a proprietary complex of five forms of Hyaluronic Acid (HA) and Hydra Collagen, plus Advanced VITISENSCE® Technology for deeper hydrationIRVINE, Calif., Aug. 27, 2024 /PRNewswire/ -- For 25 years, SkinMedica® has been at the forefront of science-based skincare solutions, and today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of its next generation hydration product: Ski ...

These stocks are the A-team for income investors.Which income investors want to buy stocks with dividends likely to decline and iffy businesses? None. Instead, income investors want practically unstoppable dividend stocks.Three Motley Fool contributors think they've identified healthcare stocks that fit the bill. Here's why they picked Abbott Laboratories (ABT 0.53%), Amgen (AMGN 1.32%), and AbbVie (ABBV 0.60%).A Dividend King with a diverse business to buy and hold for yearsDavid Jagielski (Abbott Laborato ...

29 April 2024, Rhineland-Palatinate, Ludwigshafen: Photo: Uwe Anspach/dpa (Photo by Uwe ... [+] Anspach/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesWe believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock. MRK stock trades at 14x forward earnings, versus 20x for ABBV. We think this gap in valuation will narrow in favor of Merck in the coming years, given its superior revenue growth and profitability. There is more to the co ...

AbbVie (ABBV) and partner, Genmab (GMAB) , announced that the European Commission has granted conditional marketing authorization for the expanded use of Tepkinly (epcoritamab) to treat relapsed or refractory follicular lymphoma (FL) after two or more therapies. R/R FL is a particularly difficult-to-treat form of cancer, especially in later lines of therapy, for which there is currently no standard of care treatment.The encouraging regulatory update follows the positive opinion that was adopted by the advis ...

TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapyFL is an incurable form of non-Hodgkin's lymphoma (NHL), with about 13,000 estimated cases in Western Europe alone each year1NORTH CHICAGO, Ill., Aug. 19, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that ...

These stocks dividends continue to flow and grow.What do income investors like better than a stock that pays a juicy dividend yield? The answer is easy: A stock with a juicy dividend yield that's likely to grow its dividend payout over time.Such stocks aren't as hard to find as some might think. Here are three high-yield dividend stocks to buy now that have increased their dividends for 25 years or more.1. AbbVieAbbVie's (ABBV 0.26%) forward dividend yield of over 3.2% isn't as high as it was earlier this y ...

This list of top-selling drugs could look drastically different in a few years.You might think that if a drugmaker has a top-selling drug, it would be a lock to be a top-performing stock and a no-brainer buy. That may be true in some cases. In others, it can be a source of risk as investors grow concerned about what a company's growth opportunities will look like after the relevant patent expires, especially when the drug accounts for a significant chunk of the company's sales.The three top-selling drugs in ...